Q32 Bio Inc (QTTB) - Total Assets
Based on the latest financial reports, Q32 Bio Inc (QTTB) holds total assets worth $115.87 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Q32 Bio Inc - Total Assets Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see Q32 Bio Inc (QTTB) total market value for the company's overall valuation and market capitalisation.
Q32 Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Q32 Bio Inc's total assets of $115.87 Million consist of 89.1% current assets and 10.9% non-current assets. Review Q32 Bio Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Q32 Bio Inc (QTTB) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Q32 Bio Inc's current assets represent 89.1% of total assets in 2025, an increase from 84.3% in 2016.
- Cash Position: Cash and equivalents constituted 78.2% of total assets in 2025, down from 80.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Q32 Bio Inc Competitors by Total Assets
Key competitors of Q32 Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Q32 Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.30 | 5.06 | 10.25 |
| Quick Ratio | 20.30 | 5.06 | 10.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $104.25 Million | $46.79 Million | $173.11 Million |
Q32 Bio Inc - Advanced Valuation Insights
This section examines the relationship between Q32 Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.29 |
| Latest Market Cap to Assets Ratio | 4.23 |
| Asset Growth Rate (YoY) | -33.1% |
| Total Assets | $61.78 Million |
| Market Capitalization | $261.08 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Q32 Bio Inc's assets at a significant premium (4.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Q32 Bio Inc's assets decreased by 33.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Q32 Bio Inc (2016–2025)
The table below shows the annual total assets of Q32 Bio Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.78 Million | -33.09% |
| 2024-12-31 | $92.33 Million | +96.21% |
| 2023-12-31 | $47.06 Million | -79.50% |
| 2022-12-31 | $229.53 Million | +8.41% |
| 2021-12-31 | $211.72 Million | -19.72% |
| 2020-12-31 | $263.74 Million | -15.08% |
| 2019-12-31 | $310.57 Million | +19.87% |
| 2018-12-31 | $259.09 Million | +88.39% |
| 2017-12-31 | $137.53 Million | +867.21% |
| 2016-12-31 | $14.22 Million | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical t… Read more